Nurix Reports Positive Phase 1 Trial Data for Bexobrutideg in Leukemia (CLL/SLL)

Nurix Therapeutics announced updated positive clinical data from its Phase 1a/1b study of bexobrutideg (NX-5948), a BTK degrader, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data, presented at the European Hematology Association Congress (EHA2026), showed durable responses in heavily pretreated patients and high response rates in earlier lines of treatment.

Key Details

• Phase 1a (Heavily Pretreated): In 47 evaluable patients, bexobrutideg demonstrated an 83.0% Objective Response Rate (ORR) and a median Progression-Free Survival (PFS) of 22.1 months, with a median follow-up of 22.4 months.
• Phase 1b (Earlier Lines): Showed an ORR of 92.9% in BTKi-treated patients and an 84.2% ORR in BTKi-naïve patients, indicating strong activity in earlier treatment settings.
• Safety Profile: Bexobrutideg was well-tolerated across 142 patients as of the January 1, 2026 data cutoff, with no dose-limiting toxicities reported. Treatment discontinuation due to adverse events was 5.6%.